Jove
Visualize
お問い合わせ
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー

関連する概念動画

Peptic Ulcer Disease I: Introduction01:30

Peptic Ulcer Disease I: Introduction

962
Peptic Ulcer Disease (PUD) is characterized by mucosal excavation in the esophagus, stomach, pylorus, or duodenum. It can manifest as acute or chronic based on the extent and duration of mucosal involvement.
An acute ulcer, marked by superficial erosion and minimal inflammation, swiftly resolves upon identifying and addressing the underlying cause. In contrast, a chronic ulcer persists, potentially eroding through the muscular wall and forming fibrous tissue.
Peptic ulcers can also be...
962
Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors01:24

Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors

1.4K
Peptic ulcer disease, commonly called PUD, represents a multifaceted condition characterized by disruptions in the lining of the gastrointestinal (GI)  tract. Central to the protection of the gastrointestinal lining is the mucosal-bicarbonate barrier. This physiological defense mechanism is a formidable shield against the corrosive effects of gastric acid and pepsin secretion in the stomach. Its role is pivotal in maintaining the structural integrity of the stomach's inner lining.
1.4K
Peptic Ulcer Disease IV: Management01:26

Peptic Ulcer Disease IV: Management

593
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
593
Peptic Ulcer Disease II: Pathophysiology01:28

Peptic Ulcer Disease II: Pathophysiology

2.4K
Peptic Ulcer Disease (PUD) is characterized by the development of ulcers in the stomach or duodenal mucosa. Its pathophysiology is complex, involving a balance between damaging and protective elements.
Damaging agents such as Helicobacter pylori, gastric acid, pepsin, and nonsteroidal anti-inflammatory drugs (NSAIDs) can weaken the mucosal defense, allowing hydrogen ions to infiltrate back and harm epithelial cells.
2.4K
Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies01:28

Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies

728
Peptic ulcer disease (PUD) presents with diverse symptoms depending on the location and severity of the ulcer. Clinical manifestations of peptic ulcer include dull pain and a burning sensation in the mid-epigastric region.
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.
728
Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors01:13

Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors

1.1K
Peptic ulcers, often induced by H. pylori infections or NSAID usage, arise from disruptions in the delicate balance of gastric acid production. Peptic ulcers stem from heightened gastric acid levels due to H. pylori infections or NSAID use. The protective mucus layer diminishes in the presence of these factors, allowing gastric acid to erode the stomach lining and form ulcers.
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
1.1K

こちらも読む

関連記事

共著者、ジャーナル、引用グラフによってこの研究に関連する記事。

並び替え
Same author

Long-Term Colorectal Cancer Incidence After Adenoma and Serrated Polyp Removal: Results From the Colonprev Trial.

United European gastroenterology journal·2026
Same author

Colonoscopy versus biennial FIT screening: a post hoc sustained-strategy analysis of the COLONPREV Trial.

Gut·2026
Same author

Waiting for cholecystectomy: determinants of prioritization for delayed cholecystectomy in a universal public healthcare system-post hoc analysis of RELAPSTONE cohort (WAIT-CHOL study).

BJS open·2026
Same author

Validation of Predictive Equations for Estimating Lean Soft Tissue and Fat-Free Mass in Class II-V Obesity: A Multicenter Observational Study with Implications for Bariatric Surgery Monitoring.

Journal of obesity & metabolic syndrome·2026
Same author

Editorial: Advancing gastrointestinal disease diagnosis with interpretable AI and edge computing for enhanced patient care.

Frontiers in medicine·2026
Same author

Higher Doses of Bismuth and Antibiotics Do Not Improve Helicobacter pylori Treatment Effectiveness: Results From the European Registry on Helicobacter pylori Management.

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association·2026
Same journal

Assisted dying and the silencing of medicine's next generation.

Lancet (London, England)·2026
Same journal

Linguistic pragmatism: a woman with progressive abdominal pain in Thailand.

Lancet (London, England)·2026
Same journal

Medical compartmentalisation: a patient with chromosome 22q11.2 deletion syndrome in Japan.

Lancet (London, England)·2026
Same journal

[<sup>177</sup>Lu]Lu-edotreotide versus everolimus for gastroenteropancreatic neuroendocrine tumours (COMPETE): a phase 3, multicentre, randomised, open-label, superiority trial.

Lancet (London, England)·2026
Same journal

Research priorities for characterising Bundibugyo virus.

Lancet (London, England)·2026
Same journal

Rethinking treatment sequence in advanced gastroenteropancreatic neuroendocrine tumours.

Lancet (London, England)·2026
関連記事をすべて見る

関連する実験動画

Updated: Mar 7, 2026

Author Spotlight: Advancing Early Detection and Treatment of Gastrointestinal Tumors
03:05

Author Spotlight: Advancing Early Detection and Treatment of Gastrointestinal Tumors

Published on: February 16, 2024

1.6K

胃潰瘍病

Angel Lanas1, Francis K L Chan2

  • 1Service of Digestive Diseases, University Clinic Hospital Lozano Blesa, University of Zaragoza, IIS Aragón, CIBEREHD, Zaragoza, Spain.

Lancet (London, England)
|March 1, 2017
PubMed
まとめ
この要約は機械生成です。

胃潰瘍はあまり発生しないが,抗菌剤耐性および複雑な治療法により治療が困難である. 新しい課題は,H. pyloriやNSAIDと関係のない潰瘍から生じ,更新された管理戦略を必要とします.

さらに関連する動画

Gastric Mucosa Quantitative Polymerase Chain Reaction Analysis for Detecting Helicobacter pylori and Antibiotic Resistance
05:23

Gastric Mucosa Quantitative Polymerase Chain Reaction Analysis for Detecting Helicobacter pylori and Antibiotic Resistance

Published on: March 7, 2025

873
The Dyspepsia Educational Tool As a Novel Aid in Dyspepsia Management
06:40

The Dyspepsia Educational Tool As a Novel Aid in Dyspepsia Management

Published on: June 29, 2019

7.1K

関連する実験動画

Last Updated: Mar 7, 2026

Author Spotlight: Advancing Early Detection and Treatment of Gastrointestinal Tumors
03:05

Author Spotlight: Advancing Early Detection and Treatment of Gastrointestinal Tumors

Published on: February 16, 2024

1.6K
Gastric Mucosa Quantitative Polymerase Chain Reaction Analysis for Detecting Helicobacter pylori and Antibiotic Resistance
05:23

Gastric Mucosa Quantitative Polymerase Chain Reaction Analysis for Detecting Helicobacter pylori and Antibiotic Resistance

Published on: March 7, 2025

873
The Dyspepsia Educational Tool As a Novel Aid in Dyspepsia Management
06:40

The Dyspepsia Educational Tool As a Novel Aid in Dyspepsia Management

Published on: June 29, 2019

7.1K

科学分野:

  • 胃腸内科
  • 内科 医学
  • 薬理学について

背景:

  • ヘリコバクター・パイロリ感染率の低下と陽子ポンプ阻害剤の使用の増加により,胃潰瘍疾患 (PUD) の流行率が低下しました.
  • しかし,PUDの管理はますます複雑になり,抗菌剤耐性が増加し,高齢者の間で抗血栓療法が広く使用されています.
  • H. pyloriやNSAIDとは無関係な潰瘍の数が増加しつつあり,診断と治療に特異的な課題を提示しています.

研究 の 目的:

  • 胃潰瘍に関する現在の知識と最近の進歩を総合的に説明する.
  • H. pylori 感染症の管理と PUD 合併症の治療に関する最新のガイドラインを議論する.
  • 複雑な胃潰瘍の診断と管理における満たされていないニーズを強調する.

主な方法:

  • 胃潰瘍の病原性と流行病学に関する最近の文献のレビュー.
  • H. pyloriの根絶とPUDの管理に関する現在の臨床ガイドラインの分析.
  • 抗血栓剤とNSAIDに関連したPUDの治療戦略の検討
  • 知識のギャップと将来の研究方向の特定

主要な成果:

  • H. pyloriに関連したPUDの流行率が低下しています.
  • 抗菌剤耐性および抗血栓薬の使用により,PUD管理における課題が増加しています.
  • 重要な臨床問題として,非H. pylori,非NSAIDの潰瘍の出現.
  • 最新の治療方法とさらなる研究が必要

結論:

  • 胃潰瘍の管理には,流行病学的傾向と治療上の課題に適応する必要があります.
  • 抗菌剤耐性に対処し,抗血栓治療を受けている患者の治療を最適化することが重要です.
  • 複雑な胃潰瘍を効果的に理解し,治療するにはさらなる研究が必要です.